Palmitoylethanolamide ameliorates neuroinflammation via modulating PPAR-α to promote the functional outcome after intracerebral hemorrhage
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- BV2 microglial cells treated with haemoglobin; mice with collagenase-induced intracerebral haemorrhage
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Microglial phenotype and neuroinflammation markers (NF-kB, IL-1beta, TNF-alpha) in cells and in mice, motor function, hematoma clearance, and PPAR-alpha levels, using the PPAR-alpha antagonist GW6471
What the authors reported
Palmitoylethanolamide reduced neuroinflammation by inhibiting upregulation of NF-kB, IL-1beta and TNF-alpha, both in cells and in mice, improved motor function and promoted hematoma clearance after intracerebral haemorrhage. It increased nuclear PPAR-alpha levels, and a PPAR-alpha antagonist reversed the protective effects, indicating PPAR-alpha involvement.
Limits of this study
A cell and mouse model of intracerebral haemorrhage; it cannot show effect in people. Funding and conflicts not stated in the abstract.
Source
PubMed 35469820 · doi:10.1016/j.neulet.2022.136648
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.